Complete response of metastatic renal cancer with dendritic cell vaccine.
BACKGROUND
We report a case of metastatic renal cell carcinoma that presented involution following therapy with dendritic cells.


METHODS
Male, 51-year old patient underwent left radical nephrectomy in September 1999 due to renal cell carcinoma, evolved with recurrence of the neoplasia in January 2002, confirmed by resection of the lesion. A vaccine therapy based on dendritic cells was then performed during 5 months (4 applications). After this period, there was occurrence of new lesions, whose resection revealed areas of necrosis and inflammatory infiltrate.


CONCLUSIONS
The outcome of renal cell carcinoma is influenced by prognostic factors that confer more aggressive tumor characteristics. However, in cases of recurrence, the systemic therapy with dendritic cells-based vaccine can be associated with a better outcome with regression of disease.
Dall'Oglio
Marcos
M
Discipline of Urology, Paulista School of Medicine, Federal University of São Paulo, UNIFESP, Sírio Libanês Hospital of São Paulo and Department of Immunology, ICB-USP, São Paulo, SP, Brazil. marcosdalloglio@uol.com.br
Srougi
Miguel
M
Barbuto
José A M
JA